China Compliance Update: Life Sciences — Spring 2026
In 2026, Chinese regulators have continued their focus on anti-corruption enforcement in the life sciences industry. In addition to long-standing priorities, such as fraud against China’s state-run…
Read the full articleYou might also wanna read
China creates new regulatory pathway to accelerate access to advanced biomedical therapies
The country’s new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing
biopharmadive.com·26d agoto the point: Healthcare & Life Sciences Q2/2026
......
Innovative Insights: Legal Updates in Life Sciences
European biotech leaders explore China's role in global life sciences innovation at Paris roundtable
A recent roundtable discussion at our Paris office explored the evolving role of China in the global biotechnology ecosystem and the opportu
jdsupra.com·17d agoAs US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’
As U.S. lawmakers continue to scrutinize the consequences of China’s expanding role in biotech innovation, industry insiders have been left
China's Rise in Global Clinical Trials: Regulatory Reforms and US Competitiveness
Theo Jaffee and Gabriel Dickinson speak with Cremieux about China’s rapid rise to the top of global clinical trial output. They discuss the
pocketcasts.com·18d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.